RCUS
RCUS
NYSE · Biotechnology

Arcus Biosciences Inc

$24.31
+0.19 (+0.79%)
Financial Highlights (FY 2026)
Revenue
295.45M
Net Income
-422,249,589
Gross Margin
Profit Margin
-142.9%
Rev Growth
+30.2%
D/E Ratio
0.16
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 44.4% 44.4%
Operating Margin -156.3% -140.7% -6.5% -6.4%
Profit Margin -142.9% -135.8% -8.0% -7.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 295.45M 226.99M 841.86M 875.48M
Gross Profit 374.19M 389.13M
Operating Income -461,731,419 -319,267,268 -54,514,708 -55,744,444
Net Income -422,249,589 -291,967,294 -67,570,170 -63,346,573
Gross Margin 44.4% 44.4%
Operating Margin -156.3% -140.7% -6.5% -6.4%
Profit Margin -142.9% -135.8% -8.0% -7.2%
Rev Growth +30.2% +30.2% +8.2% -1.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 207.33M 207.33M 401.69M 484.63M
Total Equity 1.32B 1.32B 1.67B 1.64B
D/E Ratio 0.16 0.16 0.24 0.30
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -449,754,650 -328,262,843 -58,220,570 -69,808,840
Free Cash Flow -41,442,789 -42,253,468